Aldeyra Therapeutics to Participate in Upcoming Conferences

November 9, 2021
PDF Version

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 9, 2021-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

  • Berenberg US CEO Conference
    Format: Analyst-Hosted Fireside Chat
    Date: Wednesday, November 10, 2021
    Time: 10:00 a.m. ET
    Note: A live and recorded webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.
  • Eyecelerator@AAO 2021
    Format: Retina Showcase Presentation
    Date: Thursday, November 11, 2021
    Time: 1:05 p.m. CT (2:05 p.m. ET)
  • Jefferies London Healthcare Conference
    Format: Analyst-Hosted Fireside Chat
    Time: Available On Demand Beginning at 8:00 a.m. GMT (3:00 a.m. ET) Thursday, November 18, 2021
    Note: A webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.
  • Ophthalmology Day at BTIG
    Format: Analyst-Hosted Fireside Chat
    Date: Tuesday, November 30, 2021
    Time: 1:00 p.m. ET

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Corporate Contact:
Joshua Reed
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
jreed@aldeyra.com

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video